Medtox's drugs of abuse test receives FDA clearance
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for Medtox Scientific’s Profile-V MedtoxScan drugs of abuse test system. The system, which is intended for professional use in a hospital laboratory setting, provides results in 10 minutes. It is made up of test devices – one-step immunochromatographic tests for human urine – and a reader. The tests can detect one or more of nine classes of drugs: amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, methadone, opiates, phencyclidine and cannabinoids. St Paul, Minnesota-based Medtox says that the reader is accurate, easy-to-use and cost-effective. It can also store 1,000 test results.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.